Biogen CEO Chris Viehbacher at the Financial Times' US Pharma and Biotech Summit, held in partnership with Endpoints News (Sarah Merians Photography for Endpoints News)

Bio­gen CEO Viehbach­er un­daunt­ed by Lil­ly's im­pend­ing Alzheimer's ther­a­py, say­ing it will ‘ex­pand’ mar­ket

NEW YORK — Fac­ing a chal­leng­ing launch for the Alzheimer’s drug Leqem­bi, Bio­gen CEO Chris Viehbach­er said he would wel­come com­pe­ti­tion from oth­er com­pa­nies, in­clud­ing Eli …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.